Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.344NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.556NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.245NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.403NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.636NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.126NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.47NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDQ.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JD.1.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBC.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.31.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FD.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.44NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GN.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FW.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.1.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.93 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.31.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GW.5.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.38NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.2.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DN.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.3.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BW.1.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.312NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.13.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.220NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.142NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.523NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.36.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.418NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.389NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.53NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.363NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HV.1.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.405NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.282NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.228NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.174NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.88 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.106 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.346NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.93NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used